rs1799963 — F2 G20210A

Second most common inherited thrombophilia; the A allele raises prothrombin levels by 30%, increasing venous thromboembolism risk 2-5 fold and is highly actionable for women considering oral contraceptives

See your personal result for F2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Prothrombin G20210A Variant — A Hidden Clotting Accelerator

Prothrombin — also called coagulation Factor II — is the precursor to thrombin, the central enzyme that converts fibrinogen into fibrin clot. The G20210A mutation in the prothrombin gene (F2) doesn't change the structure of prothrombin itself; instead, it quietly turns up its production. Carriers make 30% more prothrombin11 30% more prothrombin
Plasma prothrombin levels measured in multiple studies; homozygotes produce roughly 70% above baseline than the average person, and that excess shifts the coagulation balance toward clotting. This makes G20210A the second most common inherited thrombophilia22 second most common inherited thrombophilia
After Factor V Leiden, which affects approximately 5% of Europeans; G20210A affects 1-3% in people of European descent, with a carrier frequency of 1-3% in this population.

The Mechanism

The G20210A variant sits at position 20210 in the 3' untranslated region (3' UTR)33 3' untranslated region (3' UTR)
The non-coding tail of mRNA that controls stability, export, and how efficiently the message is translated into protein of the F2 gene on chromosome 11. This is the final nucleotide before the polyadenylation signal — the molecular "stop" marker that terminates mRNA. Replacing guanine with adenine at this position creates a more efficient cleavage site for the RNA processing machinery. The result is enhanced 3' end processing, more stable mRNA, and greater protein output44 enhanced 3' end processing, more stable mRNA, and greater protein output
Functional studies by Gehring et al. confirmed enhanced polyadenylation efficiency is the core mechanism. Prothrombin plasma levels rise 30% in heterozygotes and approximately 70% in the rare homozygotes.

More prothrombin in circulation means more thrombin available whenever coagulation is triggered, lowering the threshold for clot formation without directly disrupting the normal regulatory mechanisms. The coagulation system becomes hair-triggered — adequate for normal hemostasis but prone to excessive clotting under provocation (surgery, immobility, hormonal changes, pregnancy).

The Evidence

The variant was first described in 1996 by Poort and colleagues55 first described in 1996 by Poort and colleagues
Seminal paper in Blood identifying G20210A in 28% of families with unexplained venous thrombosis. The original cohort showed a 2.8-fold increased risk of VTE in heterozygous carriers, and this estimate has held up across decades of replication.

A pooled analysis of 8 case-control studies66 pooled analysis of 8 case-control studies
2,310 VTE cases and 3,204 controls; Study Group for Pooled-Analysis in Venous Thromboembolism established that the interaction with Factor V Leiden is clinically critical: double heterozygotes — carrying both G20210A and the Factor V Leiden mutation (rs6025) — face an odds ratio of 20 for venous thromboembolism, versus 3.8 for G20210A alone. A more recent FinnGen and UK Biobank analysis of 26,000+ carriers77 FinnGen and UK Biobank analysis of 26,000+ carriers
Published in Blood 2024 estimated the double-heterozygote OR at 5.24, suggesting the classical 20-fold estimate from smaller studies was inflated — but even the conservative biobank estimate represents an enormous absolute risk elevation.

The interaction with combined oral contraceptives (estrogen-containing pills)88 combined oral contraceptives (estrogen-containing pills)
OC use independently increases VTE risk 3-5 fold through increased coagulation factor production and reduced fibrinolysis is particularly clinically important. Women carrying G20210A who use combined oral contraceptives face an estimated 6- to 16-fold elevated VTE risk compared to non-carriers not using OCs. Progestin-only pills and non-hormonal methods (copper IUD, levonorgestrel IUD) do not carry this additional risk.

For recurrent VTE risk99 recurrent VTE risk
Meta-analysis of prospective studies through 2024, heterozygous carriers who have already experienced one VTE event face a 79% increased risk of recurrence compared to non-carriers.

Practical Implications

The actionable implications of this variant fall into three categories. First, women of reproductive age should discuss contraception choices with their physician — estrogen-containing methods carry elevated risk that is specific and avoidable. Second, any known carrier facing elective surgery, prolonged immobility (long-haul flights, hospitalization), or major hormonal changes (pregnancy, postpartum) should have this documented in their medical record and discuss thromboprophylaxis with their doctor. Third, first-degree relatives of a carrier have a 50% chance of carrying the same variant and may benefit from testing, especially before events that trigger thrombosis.

Anticoagulation after a first VTE event is managed the same way regardless of G20210A carrier status — typically 3-6 months of anticoagulation for provoked events, longer for unprovoked. The G20210A status is most relevant for the recurrence risk discussion and whether extended anticoagulation is warranted.

Interactions

The most clinically important interaction is with Factor V Leiden (rs6025, F5 R506Q)1010 Factor V Leiden (rs6025, F5 R506Q)
Factor V Leiden is the most common inherited thrombophilia, present in 5% of Europeans; double heterozygosity compounds risk multiplicatively. A person carrying both G20210A and Factor V Leiden has coagulation hyperactivated at two independent checkpoints simultaneously, producing far greater risk than either variant alone. This double heterozygous combination should be flagged as a high-priority compound interaction.

Acquired thrombophilic states — antiphospholipid syndrome, cancer, nephrotic syndrome, polycythemia vera — compound with inherited thrombophilias including G20210A in an additive or synergistic manner. The number of 20210A alleles carried (0, 1, or 2) also matters: homozygotes face substantially higher risk than heterozygotes, though homozygosity is rare (approximately 0.01% of Europeans).

Genotype Interpretations

What each possible genotype means for this variant.

GG Non-carrier Normal

Normal prothrombin production — no inherited thrombophilia from this variant

You carry two copies of the common G allele at rs1799963, meaning your prothrombin gene produces the typical baseline amount of prothrombin. This is the most common genotype, found in approximately 97% of Europeans and over 99% of people of African or East Asian descent. You do not carry the G20210A thrombophilia variant.

AG G20210A Carrier High Risk

One copy of G20210A — elevated prothrombin levels and 2-5x higher VTE risk

The G20210A variant at position rs1799963 sits in the 3' UTR of the F2 gene, where it enhances the efficiency of mRNA polyadenylation. More efficient processing leads to more stable mRNA and greater prothrombin protein output — approximately 30% more in heterozygotes. This excess prothrombin lowers the threshold for fibrin clot formation under triggering conditions.

Key provocation-specific risks: - Oral contraceptives (combined hormonal): Women with G20210A who use estrogen-containing contraceptives face an estimated 6- to 16-fold elevated VTE risk relative to non-carriers not using OCs. The interaction between G20210A and OC-induced coagulation changes is multiplicative, not merely additive. - Pregnancy and postpartum: Pregnancy itself increases VTE risk 5-10 fold. Adding G20210A to pregnancy risk requires individualized assessment; ACOG and ACCP guidelines recommend anticoagulant prophylaxis for heterozygous carriers with personal or strong family history of VTE. - Surgery and immobility: Standard surgical thromboprophylaxis protocols typically apply, but the carrier status should be documented so that extended prophylaxis can be considered for higher-risk procedures. - Air travel: Long-haul flights (>6 hours) are a mild but documented thrombosis trigger for the general population; for G20210A heterozygotes, compression stockings and hydration are especially relevant.

The variant is also associated with a modest increase in cerebral vein thrombosis risk — an uncommon but serious condition that can present as severe headache or stroke-like symptoms.

AA G20210A Homozygous High Risk

Two copies of G20210A — very high prothrombin levels and substantially elevated clotting risk

With two copies of the G20210A variant, both chromosomal copies of your F2 gene are producing mRNA at enhanced efficiency, resulting in plasma prothrombin levels approximately 70% higher than the population mean. This degree of hyperprothrombinemia creates a substantially lower threshold for pathological clotting.

Clinical management considerations for homozygotes differ meaningfully from heterozygotes: - First unprovoked VTE: Guidelines (ACCP, ISTH) consider G20210A homozygosity as a "high-risk" thrombophilia, often warranting longer anticoagulation (potentially indefinite) after a first unprovoked event, in contrast to the typical 3-6 months for low-risk provoked events. - Pregnancy: ACCP guidance recommends antepartum and postpartum LMWH prophylaxis for G20210A homozygotes regardless of personal VTE history, given the absolute risk elevation in pregnancy. - Contraception: All estrogen-containing hormonal contraceptives should be strongly avoided. - Pediatric considerations: VTE can occur in childhood for homozygotes, particularly in the setting of illness, injury, or central venous catheters.

Phenotypic expression is variable even among homozygotes — some never develop thrombosis while others experience recurrent events at young ages. This variability reflects the influence of environmental triggers, other genetic modifiers, and acquired risk factors.